iBio, Inc. (IBIO)

NCM – Real vaqt narxi. Valyuta: USD

1.61

-0.05 (-3.01%)

Yopilishda: May 12, 2026, 4:00 PM EDT

08.04.2026

iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia

IBIO-600 is a potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body composition First participants expected to be dosed in 2Q 2026 SAN DIEGO, April 08, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO) (“iBio” or “the Company”), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, today announced IBIO-600 has received Clinical Trial Notification (CTN) acknowledgement from Australia's Therapeutic Goods Administration (TGA) and ethics approval from a Human Research Ethics Committee (HREC), enabling the initiation of a first-in-human clinical trial of IBIO-600 in Australia. The Phase 1 study is a randomized, double-blind, placebo-controlled, single ascending dose trial designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of IBIO-600 in overweight and obese adult participants.

18.03.2026

iBio, Inc. (IBIO) Discusses Bispecific Antibody Program and Rationale for Targeting Pulmonary Hypertension in Heart Failure Transcript

16.03.2026

iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Company to host corporate update call on Tuesday, March 17, at 4 p.m. ET Company to host corporate update call on Tuesday, March 17, at 4 p.m. ET

09.03.2026

iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss

Study demonstrated reduction of 6.7% visceral fat and 5.2% total fat mass in obese non-human primates (NHPs) despite high-calorie diet Study demonstrated reduction of 6.7% visceral fat and 5.2% total fat mass in obese non-human primates (NHPs) despite high-calorie diet

24.02.2026

iBio to Participate in Upcoming Investor Conferences

SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), an AI-driven innovator of precision antibody therapies, today announced that Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer, and Felipe Duran, Chief Financial Officer, will participate in fireside chats at the Oppenheimer 36th Annual Healthcare Life Sciences Conference and the Leerink Global Healthcare Conference.

10.02.2026

iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update

Secured $26 Million in PIPE Financing Led by a Top-Tier Biotech Investor to Advance Preclinical Programs and Extend Cash Runway

02.02.2026

iBio, Inc. (IBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

iBio (IBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Videolar

No Data

There is no data to display

Press-relizlar

08.04.2026

iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia

16.03.2026

iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Company to host corporate update call on Tuesday, March 17, at 4 p.m. ET Company to host corporate update call on Tuesday, March 17, at 4 p.m. ET

09.03.2026

iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss

10.02.2026

iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update

Secured $26 Million in PIPE Financing Led by a Top-Tier Biotech Investor to Advance Preclinical Programs and Extend Cash Runway

iBio, Inc. (IBIO)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

iBio, Inc. (IBIO)

iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia

iBio, Inc. (IBIO) Discusses Bispecific Antibody Program and Rationale for Targeting Pulmonary Hypertension in Heart Failure Transcript

iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss

iBio to Participate in Upcoming Investor Conferences

iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update

iBio, Inc. (IBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Videolar

No Data

Press-relizlar

iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia

iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss

iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update

iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia

iBio, Inc. (IBIO) Discusses Bispecific Antibody Program and Rationale for Targeting Pulmonary Hypertension in Heart Failure Transcript

iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss

iBio to Participate in Upcoming Investor Conferences

iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update

iBio, Inc. (IBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Videolar

No Data

Press-relizlar

iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia

iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss

iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update

Search stocks

iBio, Inc. (IBIO)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

iBio, Inc. (IBIO)

iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia

iBio, Inc. (IBIO) Discusses Bispecific Antibody Program and Rationale for Targeting Pulmonary Hypertension in Heart Failure Transcript

iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss

iBio to Participate in Upcoming Investor Conferences

iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update

iBio, Inc. (IBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Videolar

No Data

Press-relizlar

iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia

iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss

iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update

iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia

iBio, Inc. (IBIO) Discusses Bispecific Antibody Program and Rationale for Targeting Pulmonary Hypertension in Heart Failure Transcript

iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss

iBio to Participate in Upcoming Investor Conferences

iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update

iBio, Inc. (IBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Videolar

No Data

Press-relizlar

iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia

iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss

iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update